Roche said it will stop development of emugrobart after clinical studies showed the drug failed to consistently improve muscle growth and motor function. Separately, Genentech moved to discontinue an antibody program intended to boost muscle in rare genetic conditions after it also failed to deliver the expected efficacy. Both companies notified patients and regulators and framed the decisions as data‑driven. Roche told patients in Europe it would halt the program because key endpoints were not met. Genentech’s decision raises questions about translatability of preclinical muscle‑preserving mechanisms into clinical benefit and has knock‑on implications for related obesity or muscle‑preservation trials that rely on similar biology. These program closures highlight the risks of late‑stage translation in muscle biology and are likely to shift investment and trial strategies for companies pursuing anabolic or muscle‑preserving therapeutics.